Bioconjugates labeled with alpha- and beta-particle emitting radionuclides as potential radiopharmaceuticals in Targeted Radionuclide Therapy.

2019/34/E/ST4/00080

Keywords

Descriptors

  • ST4_009: Chemia biologiczna
  • ST4_018: Chemia jądrowa i radiacyjna
  • NZ7_014: Farmacja, farmakoterapia, farmakologia

Panel

ST4 – Chemistry: physical chemistry/chemical physics, theoretical chemistry, analytical chemistry, inorganic chemistry, organic chemistry, method development

Host institution

Instytut Chemii i Techniki Jądrowej

Voivodeship: mazowieckie

Other projects carried out by the institution »

Principal investigator (from the host institution)

dr hab. Marek Pruszyński

Number of co-investigators in the project: 5

Call

SONATA BIS 9 – announced on 2019-06-17

Amount awarded
1 652 200 PLN
Project start date
2020-04-06
Project end date
2026-10-05
Project duration
78 months (the same as in the proposal)
Project status
Pending project

Project description

Download the project description in a pdf file

Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

Publication in academic press/journals (1)

  1. Preclinical evaluation of 225Ac-labeled single-domain antibody for the treatment of HERpos cancer

    Authors:
    Rodak M, Dekempeneer Y, Wojewódzka M, Caveliers V, Covens P, Miller BW, Sevenois MB, Bruchertseifer F, Morgenstern A, Lahoutte T, D'Huyvetter M, Pruszyński M
    Academic press:
    Molecular Cancer Therapeutics (year: 2022, volume: 21, pages: 1835–1845), Publisher: American Association for Cancer Research
    Status:
    Published
    DOI:
    10.1158/1535-7163.MCT-21-0220 – link to the publication

« New search

Graphic design and implementation: Jakub Piotrowski